Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
about
Role of HIV in amyloid metabolismIntegration of multiscale dendritic spine structure and function data into systems biology modelsContributions of academic laboratories to the discovery and development of chemical biology toolsA distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brainReference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensitiesRelative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PETMeta-analysis of amyloid-cognition relations in cognitively normal older adultsIdentification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry.Washout allometric reference method (WARM) for parametric analysis of [(11)C]PIB in human brainsCerebral Blood Flow and Aβ-Amyloid Estimates by WARM Analysis of [11C]PiB Uptake Distinguish among and between Neurodegenerative Disorders and Aging.Synapse stability in the precuneus early in the progression of Alzheimer's diseaseUse of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.The Exceptional Vulnerability of Humans to Alzheimer's Disease.Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.18F-FPYBF-2, a new F-18-labelled amyloid imaging PET tracer: first experience in 61 volunteers and 55 patients with dementia.Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
P2860
Q26824179-269605D3-6C94-44FC-A73C-CA662A44A1BCQ27003132-14379BF7-0EC2-48F1-BA3E-FC9BD6FEB54FQ28389188-FD911E0D-7F7D-468B-A847-20ED9C9FAF3CQ34381799-910B630D-4F43-49E6-BF77-A0CEA4901666Q35894473-1498BAE4-7472-4DE4-AFB7-1D0FF4C5FE9EQ36146058-84A419FF-7662-4E7D-9428-DF619706F977Q36514158-42844A45-5B64-449F-9BE0-AD4E874ED95DQ36850873-354C6E10-7601-4F40-AA3C-2D245E91AB9EQ37185672-014E14F1-B286-441B-9E9C-2708773592C4Q37346940-EB63BE39-5023-4EB2-9E97-760BFFCA7749Q37578233-57098880-8139-4685-BBF4-42658F7B0F6EQ37724226-3DEC75AD-489B-41FE-AE9C-CEC65995B8E4Q38219529-D09E4919-3162-4EE9-BF59-34E0A716359FQ38600277-8037A47E-1E83-4227-8A6A-52975230DD3EQ39291792-93ADA957-1E53-45C3-861F-764AB8058F93Q46830566-6B66DE4A-9CD3-4853-B20C-7214762C6BD8Q47407570-7CDE70D0-2ECA-477C-9344-D3C933D6078BQ47547512-FB2558C0-19D4-45F2-9B60-0E932EB0F463Q48609636-D569B8DD-6C99-4B61-86BE-5480EB5F2E48
P2860
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
@ast
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
@en
type
label
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
@ast
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
@en
prefLabel
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
@ast
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
@en
P2093
P2860
P1476
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
@en
P2093
Ann D Cohen
Chester A Mathis
Milos D Ikonomovic
William J Jagust
P2860
P356
10.1016/B978-0-12-394816-8.00002-7
P577
2012-01-01T00:00:00Z